APA (7th ed.) Citation

M, T., T, O., & H, S. (2020). Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply. The Lancet. Neurology, 19(9), 716. https://doi.org/10.1016/S1474-4422(20)30281-7

Chicago Style (17th ed.) Citation

M, Tahara, Oeda T, and Sawada H. "Seeking TranspaRINcy for Rituximab Dosing in NMOSD - Authors' Reply." The Lancet. Neurology 19, no. 9 (2020): 716. https://doi.org/10.1016/S1474-4422(20)30281-7.

MLA (9th ed.) Citation

M, Tahara, et al. "Seeking TranspaRINcy for Rituximab Dosing in NMOSD - Authors' Reply." The Lancet. Neurology, vol. 19, no. 9, 2020, p. 716, https://doi.org/10.1016/S1474-4422(20)30281-7.